Vourlekis Jason S, Szabo Eva
Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6130 Executive Blvd., Rm 2132, Bethesda, MD 20892, USA.
Dis Markers. 2004;20(2):71-85. doi: 10.1155/2004/295712.
The unacceptably high morbidity and mortality associated with the diagnosis of lung cancer mandates new approaches toward the early detection and treatment of this disease. Enhanced understanding of the molecular biology of the carcinogenic process is identifying many potential markers of risk of lung cancer occurrence as well as of poor prognosis. Identification of high risk populations who are at greatest risk of being diagnosed with and dying from lung cancer would allow delivery of more intensive screening and interventions to the individuals who are most likely to benefit from such strategies. This review examines the current status of markers of lung cancer risk, early detection, and prognosis, and their applicability to current standards of clinical care.
与肺癌诊断相关的高发病率和死亡率令人难以接受,这就需要采用新方法来早期检测和治疗这种疾病。对致癌过程分子生物学的深入了解正在识别出许多肺癌发生风险以及预后不良的潜在标志物。识别出患肺癌并死于肺癌风险最高的高危人群,将能够对最有可能从此类策略中受益的个体进行更密集的筛查和干预。本综述探讨了肺癌风险、早期检测和预后标志物的现状及其在当前临床护理标准中的适用性。